What are the recommendations for dosage and administration of Sandostatin® LAR® in patients with acromegaly?
Patients currently receiving subcutaneous Sandostatin® can be switched to a 20-mg intramuscular dose of Sandostatin® LAR® given every 4 weeks.21 After 3 months’ therapy, the dose of Sandostatin® LAR® can be decreased to 10 mg every 4 weeks or increased to a maximum of 30 mg every 4 weeks, according to response. Assessment of GH and IGF-1 levels should be performed every 6 months.
Related Questions
- What are the recommendations for dosage and administration of Sandostatin® LAR® in patients with acromegaly?
- What are the recommendations for dosage and administration of Sandostatin® in patients with acromegaly?
- Can vaccination providers charge or bill for administration of the 2009 H1N1 vaccine to patients?
